Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
Fintel on MSN9h
HC Wainwright & Co. Initiates Coverage of Perspective Therapeutics (CATX) with Buy Recommendation
Fintel reports that on March 13, 2025, HC Wainwright & Co. initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with ...
Perspective Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $10 price target Perspective is a clinical-stage ...
Oculis price target lowered to $29 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Oculis (OCS) to $29 from $30 and keeps a Buy rating on the shares following the Q4 report.
HC Wainwright Reiterates Buy Rating for Olema Pharmaceuticals (NASDAQ:OLMA)
Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on ...
Inozyme Pharma (NASDAQ:INZY) Receives Buy Rating from HC Wainwright
Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16 ...